TIGIT: a novel immunotherapy target moving from bench to bedside.
Saved in:
| Title: | TIGIT: a novel immunotherapy target moving from bench to bedside. |
|---|---|
| Authors: | Solomon BL; Oncology Division, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah School of Medicine, 2000 Circle of Hope, Suite 2100, Salt Lake City, UT, 84112, USA. Benjamin.solomon@hci.utah.edu., Garrido-Laguna I; Oncology Division, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah School of Medicine, 2000 Circle of Hope, Suite 2100, Salt Lake City, UT, 84112, USA.; Center for Investigational Therapeutics, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA. |
| Source: | Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2018 Nov; Vol. 67 (11), pp. 1659-1667. Date of Electronic Publication: 2018 Sep 19. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1432-0851 |
|---|---|
| DOI: | 10.1007/s00262-018-2246-5 |
